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Introduction
The platelet glycoprotein IIb/IIIa receptor inhibitor
abciximab (c7E3 Fab ± ReoPro1, Eli Lilly and Co,
Indianapolis IN, U.S.A.) is a highly potent antiplatelet
agent and approved for the treatment of high-risk
patients undergoing percutaneous transluminal cor-
onary angioplasty (PTCA).1 There is also a growing
body of experience in utilization of abciximab in the
treatment of peripheral vascular or cerebrovascular
disease.2,3
Abciximab binds to the platelet glycoprotein IIb/
IIIa receptor and inhibits aggregation by preventing
adhesive molecules from binding to platelet integrin.
The use of abciximab is associated with an increased
incidence of thrombocytopenia and bleeding comp-
lications.4 We report the development of an acute
thrombocytopenic reaction and major bleeding after
combined abciximab and heparin therapy in a patient
undergoing surgery for acute limb ischemia following
unsuccessful percutaneous transluminal angioplasty
(PTA) and stenting of the left superficial femoral
artery. The differential diagnosis of thrombocytopenia
and bleeding associated either with heparin or
abciximab are discussed.
Case Report
A 64-year-old male was admitted to our department
with acute ischemia of the left limb following unsuc-
cessful PTA of the superficial femoral artery. The
patient was treated in an external radiological depart-
ment. The procedure was performed in cross-over
technique under systemic heparinization (5000 U),
and was complicated by intimal dissection and throm-
botic occlusion of the femoral artery. This complica-
tion was treated by aspiration thrombectomy and
stenting. A bolus of 10 mg of abciximab was adminis-
tered to prevent rethrombosis. No additional heparin
or abciximab was administered. Despite these mea-
sures, the patient developed acute limb ischemia due
to rethrombosis. At admission, the patient's condition
was stable, limb ischemia was classified as category
IIb according to the recommended standards for
lower extremity ischemia, developed by the Joint
Council of the Society for Vascular Surgery and the
North American Chapter of the International Society
for Cardiovascular Surgery. After reviewing the arter-
iograms and clinical presentation, we decided that an
operative revascularization was the best option.
Revascularisation of the infragenicular portion of the
popliteal artery was performed using a reversed
saphenous vein graft.
The preoperative partial thromboplastin time was
54 s and an intraoperative bolus of 3000 U of heparin
was administered. The effect of heparin was reversed
at the end of the operation with protamine sulfate
(10 mg protamine per 1000 units of heparin). Post-
operative systemic heparinisation was performed
using a continuous infusion of 100 U/kg, titrated to
achieve a partial thromboplastin time twice the
control value. The platelet count before administration
of abciximab was 312 109/L, a drop was noted pre-
operatively with a platelet count of 176 109/L
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(4 h after administration of abciximab). Routine
laboratory parameters, as well as fibrinogen level
and antithrombin III, were all within the normal
range. During the first three postoperative hours,
blood loss was 41250 ml leading to a decrease in
hemoglobin from 10.7 to 4.8 gm/dl, and a +45%
decrease in hematocrit. Systemic heparinisation was
immediately stopped. The partial thromboplastin time
was 65 s at that time. At reoperation, both ana-
stomoses and the saphenous bed were explored and
diffuse non-surgical bleeding was found. The platelet
count was 486 109/L (+10 h after abciximab admin-
istration). A total of 7 U packed red blood cells and 5 U
of fresh-frozen plasma were transfused. Two pooled
platelet transfusions were necessary to maintain the
platelet count in the range of 1706 109/L. A sub-
sequent full blood cell count and coagulation profile
were all within the normal range. Heparin-induced
platelet aggregation testing was negative and systemic
heparinization was started again (100 units/kg). The
further postoperative course was uneventfully and
oral anticoagulation was started. Two days after
administration of abciximab the platelet count was
1816109/L. On discharge, at 14 days, platelet count
was 2676 109/L. Clinical and laboratory control at
6 weeks revealed no abnormalities.
Discussion
Due to the potent antiplatelet effect, the use of abcix-
imab is associated with an increased risk of bleeding.
Bleeding complications usually occur at the vascular
access site. Major bleeding is defined as intracranial
hemorrhage, a 45 g/dl decrease in hemoglobin, or a
15% decrease in hematocrit and are observed in
+3.5% of the patients.4 Another potential safety
issue is the risk of bleeding associated with emergency
surgery, if required, in the setting of near-complete
glycoprotein IIb/IIIa receptor blockade.5
The incidence of abciximab-induced acute thrombo-
cytopenia (AIT) is low, mild (51006 109/L) and
severe (5506 109/L) are observed in respectively
2.0 and 0.6% of the patients. Acute profound thrombo-
cytopenia (5206 109/L) occurs in 0.5% of the
patients who receive abciximab for the first time.4
The pharmacodynamic effect of abciximab is
reversible with platelet transfusions, which reduce
the drug's receptor occupancy on platelet surfaces to
less than the critical 50% threshold associated with
prolongation of bleeding time. This is important in
the setting of patients who require emergency surgery.
For patients who are actively bleeding, the platelet
count should be maintained at least 4506 109/L.4
The specific mechanisms for abciximab-induced
thrombocytopenia are unknown.
When bleeding complications and thrombo-
cytopenia presents following administration of two
or more anti-platelet agents, it is important to identify
which drug is the cause as misdiagnosis could have
catastrophic consequences.6,7 Due to the concomitant
use of heparin and abciximab in this case, we needed
to distinguish between heparin-induced (HIT) and
abciximab-inducedthrombocytopenia(AIT).Twotypes
of HIT have been described. Type I is characterized by
a mild transient thrombocytopenia. Type II, caused by
an IgG-mediated immune reaction, is a disorder of
delayed-onset but persistent thrombocytopenia
(51006 109/L), often associated with acute throm-
boembolic events. Type II should be suspected in any
patient who develops thrombocytopenia or throm-
boembolic events under heparin therapy. Precipitous
drops in platelet counts can be observed within 24 h
if the patient has received heparin within the last
2 months. The diagnosis is based upon the occurrence
of thrombocytopenia, exclusion of other causes of
thrombocytopenia, resolution of thrombocytopenia
after cessation of heparin therapy and demonstration
of heparin-dependent platelet antibodies.
When both heparin and abciximab are given, no test
can distinguish HIT from AIT. However, AIT behaves
differently from HIT. AIT occurs rapidly after the
administration of abciximab, HIT usually develops
over days (4 to 10 days), is not acute, and may be
associated with bleeding and thrombosis. Also helpful
in the discrimination are knowledge of patient's
exposure to heparin within the last 2 months, the
results of heparin-dependent antibody tests, and the
evolution of thrombocytopenia within the first 24 h
following administration of abciximab. Pseudothrom-
bocytopenia is an important differential diagnosis of
AIT, it is due to EDTA-dependent in vitro platelet
clumping and can be excluded by review of the per-
ipheral smear and/or repeating the platelet count
using blood anticoagulated with citrate.
When using abciximab, regular platelet counts are
necessary to detect AIT. If a thrombocytopenia is
detected, other etiologies should be ruled out and
a repeat evaluation of coagulation parameters should
be performed. In case of AIT, administration of
abciximab should stopped and the need for platelet
transfusion evaluated.
In conclusion, physicians who use abciximab
should be aware of AIT, and close monitoring of
platelet counts is necessary. Before administration
of abciximab, the risk of angioplasty failure must be
assessed, because emergency surgery carries a risk of
severe bleeding. Bleeding complications and/or
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coagulopathies in patients receiving two or more anti-
platelet agents need careful laboratory analysis to
establish the precise cause.
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